Philip Buck | Head, Us Health Outcomes And Epidemiology, Vaccines

Philip Buck, Head, Us Health Outcomes And Epidemiology, Vaccines, GlaxoSmithKline

Philip Buck leads the US Health Outcomes team at GSK Vaccines. Phil has over 15 years experience in healthcare research, with a focus on epidemiology, health economics, and psychometrics. He earned an MA and PhD in health psychology from Wayne State University and an MPH in epidemiology from the University of California, Berkeley. After post-doctoral training in infectious disease, Phil led a research team for a start-up research and consulting company and then held various positions of increasing responsibility in global health economics and outcomes research at Teva Pharmaceuticals. Phil joined US Health Outcomes at GSK in 2013, initially supporting oncology before moving to the US vaccines team in 2014. His previous vaccines responsibilities have included designing and implementing health outcomes strategies for GSK’s pertussis, influenza, and herpes zoster vaccines.


Pre-congress Workshops, April 6 @ 10:00


Workshop: Market access & regulatory challenges in vaccines The market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines.Learn how get optimal value for our vaccines and avoid the pit falls when launching a new vaccine. Topics: Panel Discussion: Older Adult Immunization Uptake: Understanding Barriers and Drivers
  • Vaccine Preventable Disease in the Medicare Population
  • Vaccine Uptake and Cost-Sharing in the Medicare Population
  • Role of Quality in Driving Vaccine Uptake
Panel Discussion: The Vaccine Pipeline and the Role of Real-World Evidence
  • Vaccine Pipeline
  • The Evolving Role of the Real-World Evidence
  • Capturing the Full Value of Vaccines
  • Novel Candidates and the Role of the ACIP
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates